The vaccinal effect of monoclonal antibodies in cancer therapy

The last two decades have brought significant improvements in cancer therapy: patients with previously fatal diseases, including acute leukaemia, non-Hodgkin’s lymphoma, Hodgkin’s disease, and germ cell tumours, now have a high expectation of cure. For patients with the more common solid tumours, including lung, colon, and breast cancer, new chemotherapeutic and hormonal agents, molecularly targeted drugs, and monoclonal antibodies have improved treatment of both early and late stage disease and have extended survival. Nevertheless, cancer remains the second leading cause of death in the Western world, and nearly one third of patients diagnosed with cancer will die of their disease....

Download Full-text

Monoclonal antibodies in cancer therapy.

Journal of Clinical Oncology ◽

10.1200/jco.1983.1.9.582 ◽

1983 ◽

Vol 1 (9) ◽

pp. 582-590 ◽

Cited By ~ 92

Author(s):

R K Oldham

Keyword(s):

Monoclonal Antibody ◽

Clinical Trials ◽

Monoclonal Antibodies ◽

Cancer Therapy ◽

Experimental Approach ◽

Preliminary Evidence ◽

Current Status ◽

Experimental Animals ◽

Specific Targeting ◽

Specific Tumor

The need for improved specificity in cancer therapy is apparent. With the advent of monoclonal antibodies, the possibility of specifically targeted therapy is being considered. Early trials of monoclonal antibody in experimental animals and humans have indicated its ability to traffic to specific tumor sites and to localize on or around the tumor cells displaying antigens to which the antibody is directed. This evidence of specific targeting, along with preliminary evidence of therapeutic efficacy for monoclonal antibodies and immunoconjugates with drugs, toxins, and isotopes is encouraging. The current status of clinical trials with monoclonal antibodies is reviewed and an example of the experimental approach for the development of immunoconjugates in animal models is presented.

Download Full-text

Immuno-PET to Optimize the Dose of Monoclonal Antibodies for Cancer Therapy: How Much Is Enough?

Journal of Nuclear Medicine ◽

10.2967/jnumed.119.225854 ◽

2019 ◽

Vol 60 (7) ◽

pp. 899-901 ◽

Cited By ~ 1

Author(s):

Raymond M. Reilly

Keyword(s):

Monoclonal Antibodies ◽

Cancer Therapy

Download Full-text

Immunoglobulin Ihhibiting Reagent®: Evaluation of a New Method for Eliminating Spurious Elevations in CA125 Caused by HAMA

The International Journal of Biological Markers ◽

10.1177/172460089601100109 ◽

1996 ◽

Vol 11 (1) ◽

pp. 46-49 ◽

Cited By ~ 6

Author(s):

S. Nicholson ◽

M. Fox ◽

A. Epenetos ◽

G. Rustin

Keyword(s):

Monoclonal Antibodies ◽

Cancer Therapy ◽

Tumour Markers ◽

New Method ◽

Automated System ◽

Mouse Serum ◽

Automated Assay ◽

Murine Monoclonal Antibodies

Cancer therapy utilising radiolabelled murine monoclonal antibodies frequently leads to the production of Human Anti-Mouse Antibodies (HAMA) in the recipient. HAMA interferes with “sandwich” immunoassays, such as those for tumour markers, rendering results unreliable. Published methods for eliminating HAMA from serum are not suitable for use in a laboratory which is processing a large number of assays using an automated system. We report on the use of Immunoglobulin Inhibiting Reagent (IIR) in CA125 assays from recipients of intraperitoneal radioimmunotherapy who had spuriously elevated results due to HAMA. IIR was found to be comparable to the admixture of mouse serum as a way of eliminating the effect of HAMA. IIR is ideally suited to use with an automated assay process.

Download Full-text